1
|
Eriksen PL, Djernes L, Vilstrup H, Ott P. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia targeting treatments. J Hepatol 2023:S0168-8278(23)00220-9. [PMID: 37061198 DOI: 10.1016/j.jhep.2023.03.042] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 03/17/2023] [Accepted: 03/26/2023] [Indexed: 04/17/2023]
Abstract
BACKGROUND & AIMS Hyperammonaemia is a key pathological feature of liver disease and the primary driver of hepatic encephalopathy (HE). However, the relative roles of increased ammonia production and reduced clearance are poorly understood as is the action of ammonia-targeting HE drugs. We aimed to quantify whole-body ammonia metabolism in healthy persons and patients with cirrhosis and to validate our method by examining the effects of glycerol phenylbutyrate and lactulose + rifaximin treatment. METHODS Ten healthy men and ten male patients with cirrhosis were investigated by 90-minute constant ammonia infusion to achieve steady-state plasma ammonia. Whole-body ammonia clearance was calculated as infusion rate divided by steady-state concentration increase and ammonia production as clearance times baseline ammonia concentration. Participants were re-investigated after the ammonia targeting interventions. RESULTS In healthy persons, ammonia clearance was 3.5 (3.1-3.9) L/min and production 49 (35-63) μmol/min. Phenylbutyrate increased clearance by 11% (4-19%, p=0.009). Patients with cirrhosis had a 20% decreased ammonia clearance of 2.7 (2.1-3.3) L/min (p = 0.02) and a nearly tripled production to 131 (102-159) μmol/min (p<0.0001). Lactulose + rifaximin reduced production by 20% (2-37%, p=0.03). The infusion was generally well-tolerated save one hyperammonaemic patient with cirrhosis with possible bleeding unrelated to the infusion who developed clinical HE that reverted when infusion was discontinued. CONCLUSIONS Whole-body ammonia clearance and production may be measured separately by the technique used. The method identified a lower clearance and a higher production in patients with cirrhosis, and showed that phenylbutyrate increases clearance, whereas lactulose + rifaximin reduces production. The method may be used to examine a range of questions related to normo-/pathophysiology and ammonia-targeting treatment mechanisms. IMPACT AND IMPLICATIONS High blood ammonia plays a key role in liver cirrhosis related brain dysfunction. However, the relative roles of increased ammonia production and reduced ammonia clearance are poorly understood as is the action of ammonia-targeting treatments. This study presents a relatively simple test to measure ammonia metabolism. By use of this test, it was possible to show that patients with liver cirrhosis have decreased ammonia clearance and increased ammonia production compared with healthy persons and to quantify distinctively different ammonia-targeting treatment effects. The test presented holds several perspectives for future studies of normal physiology and pathophysiology, not least in regard to elucidating effects of ammonia-targeting therapies. CLINICAL TRIAL NUMBER ClinicalTrials.gov (1-16-02-297-20).
Collapse
Affiliation(s)
- Peter Lykke Eriksen
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark.
| | - Lars Djernes
- Department of Anaesthesiology and Intensive Care, Viborg Regional Hospital, Denmark; Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Denmark
| | - Hendrik Vilstrup
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark
| | - Peter Ott
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark
| |
Collapse
|
2
|
Antidiabetic and antihyperlipidemic effect of Duvalia corderoyi in rats with streptozotocin-induced diabetes. Saudi J Biol Sci 2020; 27:925-934. [PMID: 32127772 PMCID: PMC7042628 DOI: 10.1016/j.sjbs.2020.01.024] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2019] [Revised: 01/16/2020] [Accepted: 01/18/2020] [Indexed: 11/25/2022] Open
Abstract
Diabetes mellitus (DM) is a metabolic syndrome distinguished with glucose increasing in blood, insulin resistance, and hyperlipidemia. It results in decease of millions of people yearly. Duvalia corderoyi is a traditional diabetes and hypertension medicine from the Arabian region. D. corderoyi extract was administered to diabetes rats for estimate its anti-diabetic and antihyperlipidemic activities in Wistar rats were induced using (60 mg/kg) of streptozotocin (STZ) intraperitoneally. The rats were randomly divided into five groups: control, diabetic, diabetic receiving glibenclamide, and two diabetic D. corderoyi-treatment groups. Rats were weighted weekly, and the biochemical analysis were carried out in serum, and liver homogenate samples. Body weight of diabetic rats was lessening significantly D. corderoyi improved body weight, glucose concentration, lipid profiles, hepatic enzymes, urea, creatinine, insulin, and HDL-C. These results are the first to indicate the potential antidiabetic and antihyperlipidemic activities of D. corderoyi.
Collapse
|
3
|
Griffin JWD, Bradshaw PC. Effects of a high protein diet and liver disease in an in silico model of human ammonia metabolism. Theor Biol Med Model 2019; 16:11. [PMID: 31366360 PMCID: PMC6670211 DOI: 10.1186/s12976-019-0109-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Accepted: 07/15/2019] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND After proteolysis, the majority of released amino acids from dietary protein are transported to the liver for gluconeogenesis or to peripheral tissues where they are used for protein synthesis and eventually catabolized, producing ammonia as a byproduct. High ammonia levels in the brain are a major contributor to the decreased neural function that occurs in several pathological conditions such as hepatic encephalopathy when liver urea cycle function is compromised. Therefore, it is important to gain a deeper understanding of human ammonia metabolism. The objective of this study was to predict changes in blood ammonia levels resulting from alterations in dietary protein intake, from liver disease, or from partial loss of urea cycle function. METHODS A simple mathematical model was created using MATLAB SimBiology and data from published studies. Simulations were performed and results analyzed to determine steady state changes in ammonia levels resulting from varying dietary protein intake and varying liver enzyme activity levels to simulate liver disease. As a toxicity reference, viability was measured in SH-SY5Y neuroblastoma cells following differentiation and ammonium chloride treatment. RESULTS Results from control simulations yielded steady state blood ammonia levels within normal physiological limits. Increasing dietary protein intake by 72% resulted in a 59% increase in blood ammonia levels. Simulations of liver cirrhosis increased blood ammonia levels by 41 to 130% depending upon the level of dietary protein intake. Simulations of heterozygous individuals carrying a loss of function allele of the urea cycle carbamoyl phosphate synthetase I (CPS1) gene resulted in more than a tripling of blood ammonia levels (from roughly 18 to 60 μM depending on dietary protein intake). The viability of differentiated SH-SY5Y cells was decreased by 14% by the addition of a slightly higher amount of ammonium chloride (90 μM). CONCLUSIONS Data from the model suggest decreasing protein consumption may be one simple strategy to decrease blood ammonia levels and minimize the risk of developing hepatic encephalopathy for many liver disease patients. In addition, the model suggests subjects who are known carriers of disease-causing CPS1 alleles may benefit from monitoring blood ammonia levels and limiting the level of protein intake if ammonia levels are high.
Collapse
Affiliation(s)
| | - Patrick C. Bradshaw
- Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN USA
| |
Collapse
|
4
|
Weiner ID, Mitch WE, Sands JM. Urea and Ammonia Metabolism and the Control of Renal Nitrogen Excretion. Clin J Am Soc Nephrol 2015; 10:1444-58. [PMID: 25078422 PMCID: PMC4527031 DOI: 10.2215/cjn.10311013] [Citation(s) in RCA: 248] [Impact Index Per Article: 27.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Renal nitrogen metabolism primarily involves urea and ammonia metabolism, and is essential to normal health. Urea is the largest circulating pool of nitrogen, excluding nitrogen in circulating proteins, and its production changes in parallel to the degradation of dietary and endogenous proteins. In addition to serving as a way to excrete nitrogen, urea transport, mediated through specific urea transport proteins, mediates a central role in the urine concentrating mechanism. Renal ammonia excretion, although often considered only in the context of acid-base homeostasis, accounts for approximately 10% of total renal nitrogen excretion under basal conditions, but can increase substantially in a variety of clinical conditions. Because renal ammonia metabolism requires intrarenal ammoniagenesis from glutamine, changes in factors regulating renal ammonia metabolism can have important effects on glutamine in addition to nitrogen balance. This review covers aspects of protein metabolism and the control of the two major molecules involved in renal nitrogen excretion: urea and ammonia. Both urea and ammonia transport can be altered by glucocorticoids and hypokalemia, two conditions that also affect protein metabolism. Clinical conditions associated with altered urine concentrating ability or water homeostasis can result in changes in urea excretion and urea transporters. Clinical conditions associated with altered ammonia excretion can have important effects on nitrogen balance.
Collapse
Affiliation(s)
- I David Weiner
- Nephrology and Hypertension Section, North Florida/South Georgia Veterans Health System, Gainesville, Florida; Division of Nephrology, Hypertension, and Transplantation, University of Florida College of Medicine, Gainesville, Florida;
| | - William E Mitch
- Nephrology Division, Baylor College of Medicine, Houston, Texas; and
| | - Jeff M Sands
- Nephrology Division, Emory University School of Medicine, Atlanta, Georgia
| |
Collapse
|
5
|
Abstract
INTRODUCTION Hepatic encephalopathy (HE) is a serious neuropsychiatric complication that is seen in patients with liver failure. The pathogenesis of HE is not entirely understood, but several hypotheses have emerged and persisted during the years. Despite the many prevalent hypotheses, most of the existing evidence point to ammonia as the main culprit behind primary and secondary symptoms making it the center of potential therapeutic options for the treatment of HE. Most treatments of hyperammonemia target the organs and metabolic processes involved in ammonia detoxification. AREAS COVERED This article provides a review of the current targets of therapy as well as the drugs used for hyperammonemia treatment. EXPERT OPINION Lactulose and rifaximin have a proven role as measures to use for secondary prophylaxis and are the mainstay of current therapy. The use of molecular adsorbent recirculating system in patients with severe HE has been proven to be efficacious, but through mechanisms that appear to be independent of ammonia. The main challenge that faces the further development of treatments for HE is finding appropriate end points, and the next step would be to provide evidence of the effectiveness of established treatments and define the role of emerging new treatments.
Collapse
Affiliation(s)
- Anna Hadjihambi
- UCL Institute for Liver and Digestive Health, UCL Medical School , Upper Third Floor, Royal Free Campus, Pond Street, NW3 2PF, London , UK +44 207 4332 794 ;
| | | | | |
Collapse
|
6
|
Matte JJ, Guay F, Girard CL. The contribution of portal drained viscera to circadian homocysteinemia in pigs. J Anim Sci 2013; 90 Suppl 4:68-70. [PMID: 23365285 DOI: 10.2527/jas.49978] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Homocysteine (Hcy) is an intermediary S-containing amino acid produced by the methylation process within all cells. It is known as a powerful pro-oxidant with multiple deleterious effects on immune and physiological functions. Blood plasma total Hcy (tHcy), the most common indicator of Hcy status, can be reduced by dietary folates or vitamin B(12) in pigs as in most mammalians. In humans, homocysteinemia is routinely assessed after an overnight fast (≥ 12 h) although information is not available on circadian tHcy changes. Using a subgroup of pigs from a study on portal appearance of vitamin B(12) after a single meal containing 0, 25 or 250 μg of cyanocobalamin, the present study aimed to report the circadian profile of postmeal blood plasma tHcy and estimate the contribution of portal drained viscera (PDV) to the systemic tHcy. Four pigs (39.7 ± 1.1 kg BW) were surgically equipped at 101.0 ± 8.2 d of age with catheters in the portal vein and carotid artery; an ultrasonic flow probe was also fitted around the portal vein for blood flow recordings. Blood samples were collected simultaneously from the 2 catheters once before meal and at least every hour during 24 h after ingestion of 1.2 kg of a vitamin-free semipurified diet. Arterial tHcy changed considerably during the 24-h postmeal period (P < 0.001; SE = 0.8). In fact, from 12.3 μM 10 min before meal, tHcy gradually reached a maximum of 23.4 μM 13 h postmeal and returned to 15.5 μM 23 h after the meal. Net fluxes of tHcy across PDV were not influenced by levels of dietary vitamin B(12), postprandial time, or their interaction (P > 0.25); average net flux did not differ from zero (P > 0.08). These results suggest that systemic Hcy following a meal originates from metabolic pools other than PDV. It appears that an overnight fast of 12 h will reflect the peak rather than the basal value for tHcy. The duration of the fasting period is therefore a critical factor for a reliable interpretation of tHcy homeostasis in pigs. Such information may be also relevant for human health and nutrition because pig is recognized as a reliable model for Hcy metabolism.
Collapse
Affiliation(s)
- J J Matte
- Dairy and Swine Research and Development Centre, Agriculture and Agri-Food Canada, Sherbrooke, Québec J1M 1Z3, Canada.
| | | | | |
Collapse
|
7
|
Al Faris NA, Al Othman ZA, Ahmad D. Effects of Mesembrrybryanthemum forsskalei Hochst seeds in lowering glucose/lipid profile in streptozotocin-induced diabetic rats. JOURNAL OF FOOD SCIENCE AND TECHNOLOGY 2011; 48:616-21. [PMID: 23572796 PMCID: PMC3551122 DOI: 10.1007/s13197-010-0152-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Revised: 02/20/2010] [Accepted: 10/15/2010] [Indexed: 11/26/2022]
Abstract
The aim of present investigation was to study the effects of Mesembryanthemum forsskalei Hochst (Samh) seeds in streptozotocin-induced diabetic rats. Thirty rats were administrated with streptozotocin to induce diabetes and 6 rats were used as untreated diabetic control. Diabetic rats were fed with 5 and 15% Samh seed alone and in combination with fatty diet i.e. 2% Cholesterol for 6 weeks. Effects of Samh seed on blood glucose levels, lipid profiles and enzyme activities of diabetic rats were examined. In addition, total cholesterol (TC), triglyceride (TG) and high density lipoprotein-cholesterol (HDL-C) were determined. Diabetic rats treated with 15% Samh seed diet were significantly decreased the level of TC (40%), TG (46%) and HDL-C (31%) respectively. Whereas, there was no significant effects observed in the glucose level in 15% Samh seeds treated rats for 6 weeks. A decrease in enzymes levels, AST (58.2%), LDH (1.6%), ALT (24.3%) and ALP (5.38%) in 5% Samh seeds diet treated rats were observed and were found near to untreated control. Findings from present study demonstrated that non fatty Samh seeds diet could have hypoglycemic and antihyperlipidemic effects in diabetic rats and could be useful model for the treatment of diabetic patients.
Collapse
Affiliation(s)
| | - Zeid A. Al Othman
- />Department of Chemistry, College of Science, King Saud University, PO Box: 2455, Riyadh, Saudi Arabia
| | - Dilshad Ahmad
- />Department of Food Science, College of Food and Agricultural Science, King Saud University, PO Box: 2460, Riyadh, Saudi Arabia
| |
Collapse
|
8
|
Olde Damink SWM, Dejong CHC, Jalan R. Review article: hyperammonaemic and catabolic consequences of upper gastrointestinal bleeding in cirrhosis. Aliment Pharmacol Ther 2009; 29:801-10. [PMID: 19183148 DOI: 10.1111/j.1365-2036.2009.03938.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Upper gastrointestinal (UGI) bleeding in patients with cirrhosis of the liver induces hyperammonaemia and leads to a catabolic cascade that precipitates life-threatening complications. The haemoglobin molecule is unique because it lacks the essential amino acid isoleucine and contains high amounts of leucine and valine. UGI bleed therefore presents the gut with protein of very low biologic value, which may be the stimulus to induce net catabolism. AIM To describe the hyperammonaemic and catabolic consequences of UGI bleeding in cirrhosis. METHODS A semi-structured literature search was performed using PubMed and article references. RESULTS It has recently been proven that ('simulation of ') a UGI bleed in patients with cirrhosis leads to impaired protein synthesis that can be restored by intravenous infusion of isoleucine. This may have therapeutic implications for the function of rapidly dividing cells and short half-life proteins such as clotting factors. Renal and small bowel ammoniagenesis were shown to be the most prominent causes for the hyperammonaemia that resulted from a UGI bleed. This provides an explanation for the therapeutic failure of the current clinical therapies that are aimed at large bowel-derived ammonia production. Isoleucine infusion did not diminish renal ammoniagenesis. CONCLUSIONS New pharmacological therapies to diminish postbleeding hyperammonaemia should target the altered inter-organ ammonia metabolism and promote ammonia excretion and/or increase the excretion of precursors of ammoniagenesis, e.g. l-ornithine-phenylacetate.
Collapse
Affiliation(s)
- S W M Olde Damink
- Department of Surgery, Maastricht University Medical Centre and Nutrition & Toxicology Research Institute Maastricht (NUTRIM), Maastricht, The Netherlands.
| | | | | |
Collapse
|
9
|
Olde Damink SWM, Jalan R, Dejong CHC. Interorgan ammonia trafficking in liver disease. Metab Brain Dis 2009; 24:169-81. [PMID: 19067143 DOI: 10.1007/s11011-008-9122-5] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2008] [Accepted: 10/28/2008] [Indexed: 12/25/2022]
Abstract
Patients with liver disease have reduced urea synthesis capacity resulting in reduced capacity to detoxify ammonia in the liver. The contribution of the gut to the hyperammonemic state observed during liver failure is mainly due to portacaval shunting and not the result of changes in the metabolism of ammonia in the gut. Small intestinal synthesis of ammonia is related to amino acid breakdown, predominantly glutamine, whereas large bowel ammonia production is caused by bacterial breakdown of amino acids and urea. The kidneys produce ammonia but adapt to liver failure in experimental portacaval shunting by reducing ammonia release into the systemic circulation. The kidneys have the ability to switch from net ammonia production to net ammonia excretion. Data from recent studies in patients with cirrhosis of the liver show that the kidneys have a major role in post upper gastrointestinal bleeding hyperammonemia. During hyperammonemia muscle takes up ammonia and plays a major role in (temporarily) detoxifying ammonia to glutamine. Net uptake of ammonia by the brain occurs in patients and experimental animals with acute and chronic liver failure. Insight will be given in recent developments on ammonia lowering therapies which are based on the information of interorgan ammonia trafficking.
Collapse
Affiliation(s)
- Steven W M Olde Damink
- Department of Surgery, Maastricht University Medical Center, PO Box 5800, Maastricht, AZ, 6202 The Netherlands.
| | | | | |
Collapse
|
10
|
Dejong CHC, van de Poll MCG, Soeters PB, Jalan R, Olde Damink SWM. Aromatic amino acid metabolism during liver failure. J Nutr 2007; 137:1579S-1585S; discussion 1597S-1598S. [PMID: 17513430 DOI: 10.1093/jn/137.6.1579s] [Citation(s) in RCA: 121] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Liver failure is associated with hepatic encephalopathy (HE). An imbalance in plasma levels of aromatic amino acids (AAA) phenylalanine, tyrosine, and tryptophan and branched chain amino acids (BCAA) and their BCAA/AAA ratio has been suggested to play a causal role in HE by enhanced brain AAA uptake and subsequently disturbed neurotransmission. Until recently, data on this subject and the role of the liver and splanchnic bed were scarce, particularly in humans, due to inaccessibility of portal and hepatic veins. Here, we discuss, against a background of relevant literature, data obtained in patients undergoing liver resection or with a transjugular intrahepatic portasystemic stent shunt (TIPSS), where these veins are accessible. The BCAA/AAA ratio remained unchanged after major liver resection, but plasma AAA levels were inversely correlated (P < 0.001) with residual liver volume, in keeping with the observed hepatic AAA uptake. In patients with stable cirrhosis and a TIPSS, the plasma BCAA/AAA ratio was lower than in controls (1.19 +/- 0.09 vs. controls: 3.63 +/- 0.34). Gastrointestinal bleeding in cirrhotics with a TIPSS induced disturbances in BCAA levels and the BCAA/AAA ratio and induced catabolism, which could partly be corrected by isoleucine administration. AAA may be important in the pathogenesis of HE, but it is unlikely that they are the sole factors. HE most likely is a syndrome with multifactorial pathogenesis, where hyperammonemia, AAA/BCAA imbalances, inflammation, brain edema, and neurotransmitter changes interact. Novel therapies to normalize AAA levels in patients with liver failure (such as the molecular adsorbent recirculating system dialysis device) should probably be combined with supplementation of e.g. isoleucine and enhancing ammonia excretion by the kidneys.
Collapse
Affiliation(s)
- Cornelis H C Dejong
- Department of Surgery, Nutrition and Toxicology Institute Maastricht, Maastricht University, the Netherlands.
| | | | | | | | | |
Collapse
|
11
|
Singer MA. Dietary protein-induced changes in excretory function: a general animal design feature. Comp Biochem Physiol B Biochem Mol Biol 2004; 136:785-801. [PMID: 14662303 DOI: 10.1016/j.cbpc.2003.08.012] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Mammals are ureotelic and respond to an increased protein intake with an increase in glomerular filtration rate and renal plasma flow. Birds and terrestrial insects are uricotelic and following a high protein intake increase tubular urate secretion by the kidney (birds) or Malpighian tubule (insects). Ureogenic fish given NH(4)Cl increase gill and renal clearance of urea and gill clearance of ammonia. Renal mass increases in mammals, birds and reptiles given a high protein intake. Thus, animals in general respond to an increase in protein intake with a change in excretory function such as to increase the clearance of the major nitrogenous end-products of protein metabolism. The components of this general animal excretory response include; a redistribution of regional perfusion with increased renal and gill blood flow, increased GFR and gill ammonia clearance, increased renal tubular urate clearance, changes in urea transport protein abundance and/or function and renal hypertrophy. Animal groups differ as to which components are accentuated. Amino acid catabolism with generation of ammonia appears to be a necessary prerequisite for this excretory response to occur. A hypothesis is put forward that ammonia itself is a regulatory molecule and an important signal communicating between amino acid catabolism following an increase in protein intake and the sequence of events leading to a change in excretory function.
Collapse
Affiliation(s)
- Michael A Singer
- Department of Medicine, Queen's University, Etherington Hall, Kingston, ON, Canada K7L 3N6.
| |
Collapse
|
12
|
van de Poll MCG, Soeters PB, Deutz NEP, Fearon KCH, Dejong CHC. Renal metabolism of amino acids: its role in interorgan amino acid exchange. Am J Clin Nutr 2004; 79:185-97. [PMID: 14749222 DOI: 10.1093/ajcn/79.2.185] [Citation(s) in RCA: 173] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The kidneys play a role in the synthesis and interorgan exchange of several amino acids. The quantitative importance of renal amino acid metabolism in the body is not, however, clear. We review here the role of the kidney in the interorgan exchange of amino acids, with emphasis on quantitative aspects. We reviewed relevant literature by using a computerized literature search (PubMed) and checking relevant references from the identified articles. Our own data are discussed in the context of the literature. The kidney takes up glutamine and metabolizes it to ammonia. This process is sensitive to pH and serves to maintain acid-base homeostasis and to excrete nitrogen. In this way, the metabolism of renal glutamine and ammonia is complementary to hepatic urea synthesis. Citrulline, derived from intestinal glutamine breakdown, is converted to arginine by the kidney. Renal phenylalanine uptake is followed by stoichiometric tyrosine release, and glycine uptake is accompanied by serine release. Certain administered oligopeptides (eg, glutamine dipeptides) are converted by the kidneys to their constituent components before they can be used in metabolic processes. The kidneys play an important role in the interorgan exchange of amino acids. Quantitatively, for several important amino acids, the kidneys are as important as the gut in intermediary metabolism. The kidneys may be crucial "mediators" of the beneficial effects of specialized, disease-specific feeding solutions such as those enriched in glutamine dipeptides.
Collapse
|
13
|
Olde Damink SWM, Jalan R, Deutz NEP, Redhead DN, Dejong CHC, Hynd P, Jalan RA, Hayes PC, Soeters PB. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 2003; 37:1277-85. [PMID: 12774005 DOI: 10.1053/jhep.2003.50221] [Citation(s) in RCA: 87] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Upper gastrointestinal (UGI) bleeding in cirrhosis is associated with enhanced ammoniagenesis, the site of which is thought to be the colon. The aims of this study were to evaluate interorgan metabolism of ammonia following an UGI bleed in patients with cirrhosis. Study 1: UGI bleed was simulated in 8 patients with cirrhosis and a transjugular intrahepatic portasystemic stent-shunt (TIPSS) by intragastric infusion of an amino acid solution that mimics the hemoglobin molecule. We sampled blood from the femoral artery and a femoral, renal, portal, and hepatic vein for 4 hours during the simulated bleed and measured plasma flows across these organs. Study 2: In 9 cirrhotic patients with an acute UGI bleed that underwent TIPSS insertion, blood was sampled from an artery and a hepatic, renal, and portal vein, and plasma flows were measured. Study 1: During the simulated bleed, arterial concentrations of ammonia increased significantly (P =.002). There was no change in ammonia production from the portal drained viscera, but renal ammonia production increased 6-fold (P =.008). In contrast to an unchanged ammonia removal by the liver, a significant increase in muscle ammonia removal was observed. Study 2: In patients with an acute UGI bleed, ammonia was only produced by the kidneys (572 [184] nmol/kg bw/min) and not by the splanchnic area (-121 [87] nmol/kg bw/min). In conclusion, enhanced renal ammonia release has an important role in the hyperammonemia that follows an UGI bleed in patients with cirrhosis. During this hyperammonemic state, muscle is the major site of ammonia removal.
Collapse
|
14
|
Olde Damink SWM, Deutz NEP, Dejong CHC, Soeters PB, Jalan R. Interorgan ammonia metabolism in liver failure. Neurochem Int 2002; 41:177-88. [PMID: 12020618 DOI: 10.1016/s0197-0186(02)00040-2] [Citation(s) in RCA: 99] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
In the post-absorptive state, ammonia is produced in equal amounts in the small and large bowel. Small intestinal synthesis of ammonia is related to amino acid breakdown, whereas large bowel ammonia production is caused by bacterial breakdown of amino acids and urea. The contribution of the gut to the hyperammonemic state observed during liver failure is mainly due to portacaval shunting and not the result of changes in the metabolism of ammonia in the gut. Patients with liver disease have reduced urea synthesis capacity and reduced peri-venous glutamine synthesis capacity, resulting in reduced capacity to detoxify ammonia in the liver. The kidneys produce ammonia but adapt to liver failure in experimental portacaval shunting by reducing ammonia release into the systemic circulation. The kidneys have the ability to switch from net ammonia production to net ammonia excretion, which is beneficial for the hyperammonemic patient. Data in experimental animals suggest that the kidneys could have a major role in post-feeding and post-haemorrhagic hyperammonemia.During hyperammonemia, muscle takes up ammonia and plays a major role in (temporarily) detoxifying ammonia to glutamine. Net uptake of ammonia by the brain occurs in patients and experimental animals with acute and chronic liver failure. Concomitant release of glutamine has been demonstrated in experimental animals, together with large increases of the cerebral cortex ammonia and glutamine concentrations. In this review we will discuss interorgan trafficking of ammonia during acute and chronic liver failure. Interorgan glutamine metabolism is also briefly discussed, since glutamine synthesis from glutamate and ammonia is an important alternative pathway of ammonia detoxification. The main ammonia producing organs are the intestines and the kidneys, whereas the major ammonia consuming organs are the liver and the muscle.
Collapse
|